According to the National Medical Insurance Administration on the 4th, since the beginning of 2023, in response to issues such as monopolistic control of sales and inflated costs of some drugs by a few enterprises, the National Medical Insurance Administration has interviewed a total of 23 enterprises throughout 2023, involving 30 varieties, with an average price reduction of over 40% for negotiated drugs. By continuously strengthening the normalization supervision of drug prices, the National Medical Insurance Administration comprehensively utilizes monitoring and early warning, inquiry and interview, credit evaluation, information disclosure and other means to effectively deal with a number of problems such as inflating raw material prices and forcing formulation prices to rise. In the first half of 2023, relevant departments discovered that Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. was suspected of colluding with three enterprises, including Wuhan Huihai Pharmaceutical, Wuhan Kede Pharmaceutical, and Hubei Minkang Pharmaceutical, to inflate the cost of raw materials by hundreds of times. At the same time, the online price of polymyxin B sulfate for injection was inflated to over 2303 yuan/tube, and it was sold domestically at an unreasonable high price dozens of times higher than the foreign price, Achieved an annual sales amount of over 4 billion yuan in just 5 years and obtained huge improper benefits. After receiving clues from relevant departments regarding the transfer of issues, in order to avoid unreasonable and high prices that continue to harm the legitimate rights and interests of patients, the National Medical Insurance Administration has held two interviews with the First Biochemical Group of Shanghai Pharmaceuticals. The online price of injection polymyxin B sulfate has been reduced to 123 yuan/tube. Based on the estimated usage in 2022, the drug alone is expected to reduce medication costs by over 3.8 billion yuan per year. The National Medical Insurance Administration stated that it supports pharmaceutical enterprises in providing high-quality, efficient, and affordable pharmaceutical products to the people through research and development innovation, consistency evaluation, and other means. It also supports pharmaceutical enterprises in compensating for costs and obtaining returns through fair and reasonable independent pricing. At the same time, it advocates for pharmaceutical enterprises to operate and price with integrity and legality, reflecting production costs, sales expenses, and corporate profits truthfully, We firmly oppose all forms of inflated costs and cashing out "sales with gold". At present, the National Medical Insurance Administration is actively promoting the rectification work of the significant differences in manufacturing costs and selling prices of some pharmaceutical consumables transferred by relevant departments. At the same time, in response to the problem of unfair and discriminatory high prices of some drugs among different provinces, it is organizing inter provincial price coordination and standardized governance to promote regional price fairness, integrity, transparency, and balance, and to promote the establishment of a national unified large market in the pharmaceutical field, Enhance fair competition in the market.. (Lai Xin She)